As a society, we’ve recognized an increasing need to rethink the value of best-in-class medicines and make a shift to consider both the science and the cost, with the goal of expanding access to high-quality medicines.


Eric Hedrick, MD, is a medical oncologist who has spent more than 20 years bringing forward several first-in-class and best-in class oncology drugs, with a particular focus on hematologic malignancies. Prior to joining EQRx, he was Chief Advisor at BeiGene, Chief Medical Officer at Epizyme and Pharmacyclics, in addition to almost a decade building out late-stage clinical development and post-marketing programs at Genentech.

Prior to joining the pharmaceutical industry, Eric was an attending physician at Memorial Sloan Kettering Cancer Center, and he served as Chief Resident of Internal Medicine at Boston City Hospital. He earned his medical degree from the University of Maryland School of Medicine and holds a bachelor’s degree from Boston University.

View All